Tag: Epidermolysis Bullosa (“EB”)

April 24, 2017 Off

Amryt starts patient testing for rare skin disease

By Dino Mustafić

Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has enroled first patient into “EASE”, the company’s pivotal Phase 3 clinical trial, which is evaluating AP101 as a potential treatment for the rare, genetic skin disorder, Epidermolysis Bullosa (“EB”).